#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0037] Covalent attachment of polypeptides or polymers to drugs may have other pharmaceutical or agricultural benefits.
1-1	0-1	[	_	_	
1-2	1-5	0037	_	_	
1-3	5-6	]	_	_	
1-4	7-15	Covalent	_	_	
1-5	16-26	attachment	_	_	
1-6	27-29	of	_	_	
1-7	30-42	polypeptides	_	_	
1-8	43-45	or	_	_	
1-9	46-54	polymers	_	_	
1-10	55-57	to	_	_	
1-11	58-63	drugs	_	_	
1-12	64-67	may	_	_	
1-13	68-72	have	_	_	
1-14	73-78	other	_	_	
1-15	79-93	pharmaceutical	_	_	
1-16	94-96	or	_	_	
1-17	97-109	agricultural	_	_	
1-18	110-118	benefits	_	_	
1-19	118-119	.	_	_	

#Text=For example, covalent attachment of polypeptides or polymers to drugs may serve to protect these drugs from chemical degradation in the gut or while circulating in the bloodstream by enveloping the drug within its folded structure until proteolytic digestion exposes and releases the drug from the polymer.
2-1	120-123	For	_	_	
2-2	124-131	example	_	_	
2-3	131-132	,	_	_	
2-4	133-141	covalent	_	_	
2-5	142-152	attachment	_	_	
2-6	153-155	of	_	_	
2-7	156-168	polypeptides	_	_	
2-8	169-171	or	_	_	
2-9	172-180	polymers	_	_	
2-10	181-183	to	_	_	
2-11	184-189	drugs	_	_	
2-12	190-193	may	_	_	
2-13	194-199	serve	_	_	
2-14	200-202	to	_	_	
2-15	203-210	protect	_	_	
2-16	211-216	these	_	_	
2-17	217-222	drugs	_	_	
2-18	223-227	from	_	_	
2-19	228-236	chemical	_	_	
2-20	237-248	degradation	_	_	
2-21	249-251	in	_	_	
2-22	252-255	the	_	_	
2-23	256-259	gut	_	_	
2-24	260-262	or	_	_	
2-25	263-268	while	_	_	
2-26	269-280	circulating	_	_	
2-27	281-283	in	_	_	
2-28	284-287	the	_	_	
2-29	288-299	bloodstream	_	_	
2-30	300-302	by	_	_	
2-31	303-313	enveloping	_	_	
2-32	314-317	the	_	_	
2-33	318-322	drug	_	_	
2-34	323-329	within	_	_	
2-35	330-333	its	_	_	
2-36	334-340	folded	_	_	
2-37	341-350	structure	_	_	
2-38	351-356	until	_	_	
2-39	357-368	proteolytic	_	_	
2-40	369-378	digestion	_	_	
2-41	379-386	exposes	_	_	
2-42	387-390	and	_	_	
2-43	391-399	releases	_	_	
2-44	400-403	the	_	_	
2-45	404-408	drug	_	_	
2-46	409-413	from	_	_	
2-47	414-417	the	_	_	
2-48	418-425	polymer	_	_	
2-49	425-426	.	_	_	

#Text=Such protective function may also have the effect of increasing the shelf-life of the drug when purified or formulated into various pharmaceutical compositions.
3-1	427-431	Such	_	_	
3-2	432-442	protective	_	_	
3-3	443-451	function	_	_	
3-4	452-455	may	_	_	
3-5	456-460	also	_	_	
3-6	461-465	have	_	_	
3-7	466-469	the	_	_	
3-8	470-476	effect	_	_	
3-9	477-479	of	_	_	
3-10	480-490	increasing	_	_	
3-11	491-494	the	_	_	
3-12	495-505	shelf-life	_	_	
3-13	506-508	of	_	_	
3-14	509-512	the	_	_	
3-15	513-517	drug	_	_	
3-16	518-522	when	_	_	
3-17	523-531	purified	_	_	
3-18	532-534	or	_	_	
3-19	535-545	formulated	_	_	
3-20	546-550	into	_	_	
3-21	551-558	various	_	_	
3-22	559-573	pharmaceutical	_	_	
3-23	574-586	compositions	_	_	
3-24	586-587	.	_	_	

#Text=Depending on the specific linkage and position of the drug in the polymer, steric hindrances may also serve to lower the affinity of the drug for a particular receptor or a sub-class of binding sites until complete digestion of polymer is achieved to release the drug.
4-1	588-597	Depending	_	_	
4-2	598-600	on	_	_	
4-3	601-604	the	_	_	
4-4	605-613	specific	_	_	
4-5	614-621	linkage	_	_	
4-6	622-625	and	_	_	
4-7	626-634	position	_	_	
4-8	635-637	of	_	_	
4-9	638-641	the	_	_	
4-10	642-646	drug	_	_	
4-11	647-649	in	_	_	
4-12	650-653	the	_	_	
4-13	654-661	polymer	_	_	
4-14	661-662	,	_	_	
4-15	663-669	steric	_	_	
4-16	670-680	hindrances	_	_	
4-17	681-684	may	_	_	
4-18	685-689	also	_	_	
4-19	690-695	serve	_	_	
4-20	696-698	to	_	_	
4-21	699-704	lower	_	_	
4-22	705-708	the	_	_	
4-23	709-717	affinity	_	_	
4-24	718-720	of	_	_	
4-25	721-724	the	_	_	
4-26	725-729	drug	_	_	
4-27	730-733	for	_	_	
4-28	734-735	a	_	_	
4-29	736-746	particular	_	_	
4-30	747-755	receptor	_	_	
4-31	756-758	or	_	_	
4-32	759-760	a	_	_	
4-33	761-770	sub-class	_	_	
4-34	771-773	of	_	_	
4-35	774-781	binding	_	_	
4-36	782-787	sites	_	_	
4-37	788-793	until	_	_	
4-38	794-802	complete	_	_	
4-39	803-812	digestion	_	_	
4-40	813-815	of	_	_	
4-41	816-823	polymer	_	_	
4-42	824-826	is	_	_	
4-43	827-835	achieved	_	_	
4-44	836-838	to	_	_	
4-45	839-846	release	_	_	
4-46	847-850	the	_	_	
4-47	851-855	drug	_	_	
4-48	855-856	.	_	_	

#Text=Such final "activation" or release of the drug may occur at sites of action to allow for greater targeting of its effect in peripheral tissues, thus providing a "pro-pro-drug" approach that combines properties of sustained release and targeted activity.
5-1	857-861	Such	_	_	
5-2	862-867	final	_	_	
5-3	868-869	"	_	_	
5-4	869-879	activation	_	_	
5-5	879-880	"	_	_	
5-6	881-883	or	_	_	
5-7	884-891	release	_	_	
5-8	892-894	of	_	_	
5-9	895-898	the	_	_	
5-10	899-903	drug	_	_	
5-11	904-907	may	_	_	
5-12	908-913	occur	_	_	
5-13	914-916	at	_	_	
5-14	917-922	sites	_	_	
5-15	923-925	of	_	_	
5-16	926-932	action	_	_	
5-17	933-935	to	_	_	
5-18	936-941	allow	_	_	
5-19	942-945	for	_	_	
5-20	946-953	greater	_	_	
5-21	954-963	targeting	_	_	
5-22	964-966	of	_	_	
5-23	967-970	its	_	_	
5-24	971-977	effect	_	_	
5-25	978-980	in	_	_	
5-26	981-991	peripheral	_	_	
5-27	992-999	tissues	_	_	
5-28	999-1000	,	_	_	
5-29	1001-1005	thus	_	_	
5-30	1006-1015	providing	_	_	
5-31	1016-1017	a	_	_	
5-32	1018-1019	"	_	_	
5-33	1019-1031	pro-pro-drug	_	_	
5-34	1031-1032	"	_	_	
5-35	1033-1041	approach	_	_	
5-36	1042-1046	that	_	_	
5-37	1047-1055	combines	_	_	
5-38	1056-1066	properties	_	_	
5-39	1067-1069	of	_	_	
5-40	1070-1079	sustained	_	_	
5-41	1080-1087	release	_	_	
5-42	1088-1091	and	_	_	
5-43	1092-1100	targeted	_	_	
5-44	1101-1109	activity	_	_	
5-45	1109-1110	.	_	_	

#Text=Steric protection provided by the polymer or peptide linkage to a drug may also serve to protect the drug from modification and clearance before it has had the opportunity to exert its biological effect.
6-1	1111-1117	Steric	_	_	
6-2	1118-1128	protection	_	_	
6-3	1129-1137	provided	_	_	
6-4	1138-1140	by	_	_	
6-5	1141-1144	the	_	_	
6-6	1145-1152	polymer	_	_	
6-7	1153-1155	or	_	_	
6-8	1156-1163	peptide	_	_	
6-9	1164-1171	linkage	_	_	
6-10	1172-1174	to	_	_	
6-11	1175-1176	a	_	_	
6-12	1177-1181	drug	_	_	
6-13	1182-1185	may	_	_	
6-14	1186-1190	also	_	_	
6-15	1191-1196	serve	_	_	
6-16	1197-1199	to	_	_	
6-17	1200-1207	protect	_	_	
6-18	1208-1211	the	_	_	
6-19	1212-1216	drug	_	_	
6-20	1217-1221	from	_	_	
6-21	1222-1234	modification	_	_	
6-22	1235-1238	and	_	_	
6-23	1239-1248	clearance	_	_	
6-24	1249-1255	before	_	_	
6-25	1256-1258	it	_	_	
6-26	1259-1262	has	_	_	
6-27	1263-1266	had	_	_	
6-28	1267-1270	the	_	_	
6-29	1271-1282	opportunity	_	_	
6-30	1283-1285	to	_	_	
6-31	1286-1291	exert	_	_	
6-32	1292-1295	its	_	_	
6-33	1296-1306	biological	_	_	
6-34	1307-1313	effect	_	_	
6-35	1313-1314	.	_	_	

#Text=For example, a peptide-linked amphetamine compound may be resistant to monoamine oxidase degradation.
7-1	1315-1318	For	_	_	
7-2	1319-1326	example	_	_	
7-3	1326-1327	,	_	_	
7-4	1328-1329	a	_	_	
7-5	1330-1344	peptide-linked	_	_	
7-6	1345-1356	amphetamine	_	_	
7-7	1357-1365	compound	_	_	
7-8	1366-1369	may	_	_	
7-9	1370-1372	be	_	_	
7-10	1373-1382	resistant	_	_	
7-11	1383-1385	to	_	_	
7-12	1386-1395	monoamine	_	_	
7-13	1396-1403	oxidase	_	_	
7-14	1404-1415	degradation	_	_	
7-15	1415-1416	.	_	_	

#Text=Yet another benefit of covalent attachment of polypeptides or polymers may be improved solubility of certain drugs in aqueous environments.
#Text=[0038] A number of techniques for synthesizing polypeptide or peptide-linked molecules in vitro have been described.
8-1	1417-1420	Yet	_	_	
8-2	1421-1428	another	_	_	
8-3	1429-1436	benefit	_	_	
8-4	1437-1439	of	_	_	
8-5	1440-1448	covalent	_	_	
8-6	1449-1459	attachment	_	_	
8-7	1460-1462	of	_	_	
8-8	1463-1475	polypeptides	_	_	
8-9	1476-1478	or	_	_	
8-10	1479-1487	polymers	_	_	
8-11	1488-1491	may	_	_	
8-12	1492-1494	be	_	_	
8-13	1495-1503	improved	_	_	
8-14	1504-1514	solubility	_	_	
8-15	1515-1517	of	_	_	
8-16	1518-1525	certain	_	_	
8-17	1526-1531	drugs	_	_	
8-18	1532-1534	in	_	_	
8-19	1535-1542	aqueous	_	_	
8-20	1543-1555	environments	_	_	
8-21	1555-1556	.	_	_	
8-22	1557-1558	[	_	_	
8-23	1558-1562	0038	_	_	
8-24	1562-1563	]	_	_	
8-25	1564-1565	A	_	_	
8-26	1566-1572	number	_	_	
8-27	1573-1575	of	_	_	
8-28	1576-1586	techniques	_	_	
8-29	1587-1590	for	_	_	
8-30	1591-1603	synthesizing	_	_	
8-31	1604-1615	polypeptide	_	_	
8-32	1616-1618	or	_	_	
8-33	1619-1633	peptide-linked	_	_	
8-34	1634-1643	molecules	_	_	
8-35	1644-1646	in	_	_	
8-36	1647-1652	vitro	_	_	
8-37	1653-1657	have	_	_	
8-38	1658-1662	been	_	_	
8-39	1663-1672	described	_	_	
8-40	1672-1673	.	_	_	

#Text=For example, stepwise blocking/de-blocking methods have been known in the art for many years as a way of building polypeptide molecules.
9-1	1674-1677	For	_	_	
9-2	1678-1685	example	_	_	
9-3	1685-1686	,	_	_	
9-4	1687-1695	stepwise	_	_	
9-5	1696-1704	blocking	_	_	
9-6	1704-1705	/	_	_	
9-7	1705-1716	de-blocking	_	_	
9-8	1717-1724	methods	_	_	
9-9	1725-1729	have	_	_	
9-10	1730-1734	been	_	_	
9-11	1735-1740	known	_	_	
9-12	1741-1743	in	_	_	
9-13	1744-1747	the	_	_	
9-14	1748-1751	art	_	_	
9-15	1752-1755	for	_	_	
9-16	1756-1760	many	_	_	
9-17	1761-1766	years	_	_	
9-18	1767-1769	as	_	_	
9-19	1770-1771	a	_	_	
9-20	1772-1775	way	_	_	
9-21	1776-1778	of	_	_	
9-22	1779-1787	building	_	_	
9-23	1788-1799	polypeptide	_	_	
9-24	1800-1809	molecules	_	_	
9-25	1809-1810	.	_	_	

#Text=However, these methods generally require multiple chemical steps for the addition of each amino acid to the polymer resulting in a time-consuming process with a low product yield.
#Text=[0039] An alternative, solution-based approach to synthesizing a peptide molecule may be achieved using a carbodiimide method.
10-1	1811-1818	However	_	_	
10-2	1818-1819	,	_	_	
10-3	1820-1825	these	_	_	
10-4	1826-1833	methods	_	_	
10-5	1834-1843	generally	_	_	
10-6	1844-1851	require	_	_	
10-7	1852-1860	multiple	_	_	
10-8	1861-1869	chemical	_	_	
10-9	1870-1875	steps	_	_	
10-10	1876-1879	for	_	_	
10-11	1880-1883	the	_	_	
10-12	1884-1892	addition	_	_	
10-13	1893-1895	of	_	_	
10-14	1896-1900	each	_	_	
10-15	1901-1906	amino	_	_	
10-16	1907-1911	acid	_	_	
10-17	1912-1914	to	_	_	
10-18	1915-1918	the	_	_	
10-19	1919-1926	polymer	_	_	
10-20	1927-1936	resulting	_	_	
10-21	1937-1939	in	_	_	
10-22	1940-1941	a	_	_	
10-23	1942-1956	time-consuming	_	_	
10-24	1957-1964	process	_	_	
10-25	1965-1969	with	_	_	
10-26	1970-1971	a	_	_	
10-27	1972-1975	low	_	_	
10-28	1976-1983	product	_	_	
10-29	1984-1989	yield	_	_	
10-30	1989-1990	.	_	_	
10-31	1991-1992	[	*[1]	12-1[2_1]	
10-32	1992-1996	0039	*[1]	_	
10-33	1996-1997	]	*[1]	_	
10-34	1998-2000	An	*[1]	_	
10-35	2001-2012	alternative	*[1]	_	
10-36	2012-2013	,	*[1]	_	
10-37	2014-2028	solution-based	*[1]	_	
10-38	2029-2037	approach	*[1]	_	
10-39	2038-2040	to	*[1]	_	
10-40	2041-2053	synthesizing	*[1]	_	
10-41	2054-2055	a	*[1]	_	
10-42	2056-2063	peptide	*[1]	_	
10-43	2064-2072	molecule	*[1]	_	
10-44	2073-2076	may	*[1]	_	
10-45	2077-2079	be	*[1]	_	
10-46	2080-2088	achieved	*[1]	_	
10-47	2089-2094	using	*[1]	_	
10-48	2095-2096	a	*[1]	_	
10-49	2097-2109	carbodiimide	*[1]	_	
10-50	2110-2116	method	*[1]	_	
10-51	2116-2117	.	*[1]	_	

#Text=This approach generally relies on the use of a carbodiimide molecule (e.g., dicyclohexylcarbodiimide (DCC), etc.) to activate a carboxyl (e.g., --COOH) group of one compound, such as an amino acid, to produce a highly reactive intermediate which may then react and bond to other compounds or molecules, such as through an amino group of an amino acid to form a peptide bond.
11-1	2118-2122	This	_	_	
11-2	2123-2131	approach	_	_	
11-3	2132-2141	generally	_	_	
11-4	2142-2148	relies	_	_	
11-5	2149-2151	on	_	_	
11-6	2152-2155	the	_	_	
11-7	2156-2159	use	_	_	
11-8	2160-2162	of	_	_	
11-9	2163-2164	a	_	_	
11-10	2165-2177	carbodiimide	_	_	
11-11	2178-2186	molecule	_	_	
11-12	2187-2188	(	_	_	
11-13	2188-2191	e.g	_	_	
11-14	2191-2192	.	_	_	
11-15	2192-2193	,	_	_	
11-16	2194-2218	dicyclohexylcarbodiimide	_	_	
11-17	2219-2220	(	_	_	
11-18	2220-2223	DCC	_	_	
11-19	2223-2224	)	_	_	
11-20	2224-2225	,	_	_	
11-21	2226-2229	etc	_	_	
11-22	2229-2230	.	_	_	
11-23	2230-2231	)	_	_	
11-24	2232-2234	to	_	_	
11-25	2235-2243	activate	_	_	
11-26	2244-2245	a	_	_	
11-27	2246-2254	carboxyl	_	_	
11-28	2255-2256	(	_	_	
11-29	2256-2259	e.g	_	_	
11-30	2259-2260	.	_	_	
11-31	2260-2261	,	_	_	
11-32	2262-2263	-	_	_	
11-33	2263-2264	-	_	_	
11-34	2264-2268	COOH	_	_	
11-35	2268-2269	)	_	_	
11-36	2270-2275	group	_	_	
11-37	2276-2278	of	_	_	
11-38	2279-2282	one	_	_	
11-39	2283-2291	compound	_	_	
11-40	2291-2292	,	_	_	
11-41	2293-2297	such	_	_	
11-42	2298-2300	as	_	_	
11-43	2301-2303	an	_	_	
11-44	2304-2309	amino	_	_	
11-45	2310-2314	acid	_	_	
11-46	2314-2315	,	_	_	
11-47	2316-2318	to	_	_	
11-48	2319-2326	produce	_	_	
11-49	2327-2328	a	_	_	
11-50	2329-2335	highly	_	_	
11-51	2336-2344	reactive	_	_	
11-52	2345-2357	intermediate	_	_	
11-53	2358-2363	which	_	_	
11-54	2364-2367	may	_	_	
11-55	2368-2372	then	_	_	
11-56	2373-2378	react	_	_	
11-57	2379-2382	and	_	_	
11-58	2383-2387	bond	_	_	
11-59	2388-2390	to	_	_	
11-60	2391-2396	other	_	_	
11-61	2397-2406	compounds	_	_	
11-62	2407-2409	or	_	_	
11-63	2410-2419	molecules	_	_	
11-64	2419-2420	,	_	_	
11-65	2421-2425	such	_	_	
11-66	2426-2428	as	_	_	
11-67	2429-2436	through	_	_	
11-68	2437-2439	an	_	_	
11-69	2440-2445	amino	_	_	
11-70	2446-2451	group	_	_	
11-71	2452-2454	of	_	_	
11-72	2455-2457	an	_	_	
11-73	2458-2463	amino	_	_	
11-74	2464-2468	acid	_	_	
11-75	2469-2471	to	_	_	
11-76	2472-2476	form	_	_	
11-77	2477-2478	a	_	_	
11-78	2479-2486	peptide	_	_	
11-79	2487-2491	bond	_	_	
11-80	2491-2492	.	_	_	

#Text=This method may be used to link two amino acids together or to couple an amino acid (or preformed peptide) to an active agent.
12-1	2493-2497	This	*[2]	_	
12-2	2498-2504	method	*[2]	_	
12-3	2505-2508	may	_	_	
12-4	2509-2511	be	_	_	
12-5	2512-2516	used	_	_	
12-6	2517-2519	to	_	_	
12-7	2520-2524	link	_	_	
12-8	2525-2528	two	_	_	
12-9	2529-2534	amino	_	_	
12-10	2535-2540	acids	_	_	
12-11	2541-2549	together	_	_	
12-12	2550-2552	or	_	_	
12-13	2553-2555	to	_	_	
12-14	2556-2562	couple	_	_	
12-15	2563-2565	an	_	_	
12-16	2566-2571	amino	_	_	
12-17	2572-2576	acid	_	_	
12-18	2577-2578	(	_	_	
12-19	2578-2580	or	_	_	
12-20	2581-2590	preformed	_	_	
12-21	2591-2598	peptide	_	_	
12-22	2598-2599	)	_	_	
12-23	2600-2602	to	_	_	
12-24	2603-2605	an	_	_	
12-25	2606-2612	active	_	_	
12-26	2613-2618	agent	_	_	
12-27	2618-2619	.	_	_	

#Text=However, this carbodiimide reaction scheme is not capable of self-polymerization and merely provides a coupling or linking mechanism for joining two molecules.
13-1	2620-2627	However	_	_	
13-2	2627-2628	,	_	_	
13-3	2629-2633	this	_	_	
13-4	2634-2646	carbodiimide	_	_	
13-5	2647-2655	reaction	_	_	
13-6	2656-2662	scheme	_	_	
13-7	2663-2665	is	_	_	
13-8	2666-2669	not	_	_	
13-9	2670-2677	capable	_	_	
13-10	2678-2680	of	_	_	
13-11	2681-2700	self-polymerization	_	_	
13-12	2701-2704	and	_	_	
13-13	2705-2711	merely	_	_	
13-14	2712-2720	provides	_	_	
13-15	2721-2722	a	_	_	
13-16	2723-2731	coupling	_	_	
13-17	2732-2734	or	_	_	
13-18	2735-2742	linking	_	_	
13-19	2743-2752	mechanism	_	_	
13-20	2753-2756	for	_	_	
13-21	2757-2764	joining	_	_	
13-22	2765-2768	two	_	_	
13-23	2769-2778	molecules	_	_	
13-24	2778-2779	.	_	_	

#Text=Once a carbodiimide-activated molecule, such as a carbodiimide-activated amino acid, is allowed to react with another compound, the reaction is complete.
14-1	2780-2784	Once	_	_	
14-2	2785-2786	a	_	_	
14-3	2787-2809	carbodiimide-activated	_	_	
14-4	2810-2818	molecule	_	_	
14-5	2818-2819	,	_	_	
14-6	2820-2824	such	_	_	
14-7	2825-2827	as	_	_	
14-8	2828-2829	a	_	_	
14-9	2830-2852	carbodiimide-activated	_	_	
14-10	2853-2858	amino	_	_	
14-11	2859-2863	acid	_	_	
14-12	2863-2864	,	_	_	
14-13	2865-2867	is	_	_	
14-14	2868-2875	allowed	_	_	
14-15	2876-2878	to	_	_	
14-16	2879-2884	react	_	_	
14-17	2885-2889	with	_	_	
14-18	2890-2897	another	_	_	
14-19	2898-2906	compound	_	_	
14-20	2906-2907	,	_	_	
14-21	2908-2911	the	_	_	
14-22	2912-2920	reaction	_	_	
14-23	2921-2923	is	_	_	
14-24	2924-2932	complete	_	_	
14-25	2932-2933	.	_	_	

#Text=To synthesize a polypeptide containing, for example, three or more amino acids using the carbodiimide method, a stepwise approach would be necessary to carry out repeated rounds of activation and coupling.
15-1	2934-2936	To	_	_	
15-2	2937-2947	synthesize	_	_	
15-3	2948-2949	a	_	_	
15-4	2950-2961	polypeptide	_	_	
15-5	2962-2972	containing	_	_	
15-6	2972-2973	,	_	_	
15-7	2974-2977	for	_	_	
15-8	2978-2985	example	_	_	
15-9	2985-2986	,	_	_	
15-10	2987-2992	three	_	_	
15-11	2993-2995	or	_	_	
15-12	2996-3000	more	_	_	
15-13	3001-3006	amino	_	_	
15-14	3007-3012	acids	_	_	
15-15	3013-3018	using	_	_	
15-16	3019-3022	the	_	_	
15-17	3023-3035	carbodiimide	_	_	
15-18	3036-3042	method	_	_	
15-19	3042-3043	,	_	_	
15-20	3044-3045	a	_	_	
15-21	3046-3054	stepwise	_	_	
15-22	3055-3063	approach	_	_	
15-23	3064-3069	would	_	_	
15-24	3070-3072	be	_	_	
15-25	3073-3082	necessary	_	_	
15-26	3083-3085	to	_	_	
15-27	3086-3091	carry	_	_	
15-28	3092-3095	out	_	_	
15-29	3096-3104	repeated	_	_	
15-30	3105-3111	rounds	_	_	
15-31	3112-3114	of	_	_	
15-32	3115-3125	activation	_	_	
15-33	3126-3129	and	_	_	
15-34	3130-3138	coupling	_	_	
15-35	3138-3139	.	_	_	

#Text=Such a step-wise approach is a time-consuming process having a substantial reduction in yield to carry out these multiple reaction steps.
16-1	3140-3144	Such	_	_	
16-2	3145-3146	a	_	_	
16-3	3147-3156	step-wise	_	_	
16-4	3157-3165	approach	_	_	
16-5	3166-3168	is	_	_	
16-6	3169-3170	a	_	_	
16-7	3171-3185	time-consuming	_	_	
16-8	3186-3193	process	_	_	
16-9	3194-3200	having	_	_	
16-10	3201-3202	a	_	_	
16-11	3203-3214	substantial	_	_	
16-12	3215-3224	reduction	_	_	
16-13	3225-3227	in	_	_	
16-14	3228-3233	yield	_	_	
16-15	3234-3236	to	_	_	
16-16	3237-3242	carry	_	_	
16-17	3243-3246	out	_	_	
16-18	3247-3252	these	_	_	
16-19	3253-3261	multiple	_	_	
16-20	3262-3270	reaction	_	_	
16-21	3271-3276	steps	_	_	
16-22	3276-3277	.	_	_	

#Text=Furthermore, any additional side groups which might react with a carbodiimide-activated intermediate may need to be blocked to avoid formation of unintended and undesired by-products.
17-1	3278-3289	Furthermore	_	_	
17-2	3289-3290	,	_	_	
17-3	3291-3294	any	_	_	
17-4	3295-3305	additional	_	_	
17-5	3306-3310	side	_	_	
17-6	3311-3317	groups	_	_	
17-7	3318-3323	which	_	_	
17-8	3324-3329	might	_	_	
17-9	3330-3335	react	_	_	
17-10	3336-3340	with	_	_	
17-11	3341-3342	a	_	_	
17-12	3343-3365	carbodiimide-activated	_	_	
17-13	3366-3378	intermediate	_	_	
17-14	3379-3382	may	_	_	
17-15	3383-3387	need	_	_	
17-16	3388-3390	to	_	_	
17-17	3391-3393	be	_	_	
17-18	3394-3401	blocked	_	_	
17-19	3402-3404	to	_	_	
17-20	3405-3410	avoid	_	_	
17-21	3411-3420	formation	_	_	
17-22	3421-3423	of	_	_	
17-23	3424-3434	unintended	_	_	
17-24	3435-3438	and	_	_	
17-25	3439-3448	undesired	_	_	
17-26	3449-3460	by-products	_	_	
17-27	3460-3461	.	_	_	

#Text=In addition, carbodiimides tend to form racemic mixtures of amino acids which may be incorporated into peptide-linked molecules or polymers.
18-1	3462-3464	In	_	_	
18-2	3465-3473	addition	_	_	
18-3	3473-3474	,	_	_	
18-4	3475-3488	carbodiimides	_	_	
18-5	3489-3493	tend	_	_	
18-6	3494-3496	to	_	_	
18-7	3497-3501	form	_	_	
18-8	3502-3509	racemic	_	_	
18-9	3510-3518	mixtures	_	_	
18-10	3519-3521	of	_	_	
18-11	3522-3527	amino	_	_	
18-12	3528-3533	acids	_	_	
18-13	3534-3539	which	_	_	
18-14	3540-3543	may	_	_	
18-15	3544-3546	be	_	_	
18-16	3547-3559	incorporated	_	_	
18-17	3560-3564	into	_	_	
18-18	3565-3579	peptide-linked	_	_	
18-19	3580-3589	molecules	_	_	
18-20	3590-3592	or	_	_	
18-21	3593-3601	polymers	_	_	
18-22	3601-3602	.	_	_	

#Text=Considering that most naturally occurring amino acids are L-amino acids, racemization may make enzyme digestion of carbodiimide-produced polypeptides difficult or impossible, and a large proportion of active agents incorporated into carbodiimide-produced polypeptides or amino acid conjugates may be rendered inaccessible or biologically inactive.
19-1	3603-3614	Considering	_	_	
19-2	3615-3619	that	_	_	
19-3	3620-3624	most	_	_	
19-4	3625-3634	naturally	_	_	
19-5	3635-3644	occurring	_	_	
19-6	3645-3650	amino	_	_	
19-7	3651-3656	acids	_	_	
19-8	3657-3660	are	_	_	
19-9	3661-3668	L-amino	_	_	
19-10	3669-3674	acids	_	_	
19-11	3674-3675	,	_	_	
19-12	3676-3688	racemization	_	_	
19-13	3689-3692	may	_	_	
19-14	3693-3697	make	_	_	
19-15	3698-3704	enzyme	_	_	
19-16	3705-3714	digestion	_	_	
19-17	3715-3717	of	_	_	
19-18	3718-3739	carbodiimide-produced	_	_	
19-19	3740-3752	polypeptides	_	_	
19-20	3753-3762	difficult	_	_	
19-21	3763-3765	or	_	_	
19-22	3766-3776	impossible	_	_	
19-23	3776-3777	,	_	_	
19-24	3778-3781	and	_	_	
19-25	3782-3783	a	_	_	
19-26	3784-3789	large	_	_	
19-27	3790-3800	proportion	_	_	
19-28	3801-3803	of	_	_	
19-29	3804-3810	active	_	_	
19-30	3811-3817	agents	_	_	
19-31	3818-3830	incorporated	_	_	
19-32	3831-3835	into	_	_	
19-33	3836-3857	carbodiimide-produced	_	_	
19-34	3858-3870	polypeptides	_	_	
19-35	3871-3873	or	_	_	
19-36	3874-3879	amino	_	_	
19-37	3880-3884	acid	_	_	
19-38	3885-3895	conjugates	_	_	
19-39	3896-3899	may	_	_	
19-40	3900-3902	be	_	_	
19-41	3903-3911	rendered	_	_	
19-42	3912-3924	inaccessible	_	_	
19-43	3925-3927	or	_	_	
19-44	3928-3940	biologically	_	_	
19-45	3941-3949	inactive	_	_	
19-46	3949-3950	.	_	_	

#Text=Although the addition of triazolol compounds (e.g., hydroxybenzotriazole (HOBt), etc.) have reduced this racemic effect, carbodiimide-based methods remain a less practical approach for synthesizing polypeptide molecules.
#Text=[0040] One effective method for synthesizing polypeptides or peptide-linked polymers that overcomes issues of racemization and non-spontaneous polymerization is the Fuchs-Farthing approach of generating highly reactive N-carboxyanhydride (NCA) intermediates of compounds or amino acids.
20-1	3951-3959	Although	_	_	
20-2	3960-3963	the	_	_	
20-3	3964-3972	addition	_	_	
20-4	3973-3975	of	_	_	
20-5	3976-3985	triazolol	_	_	
20-6	3986-3995	compounds	_	_	
20-7	3996-3997	(	_	_	
20-8	3997-4000	e.g	_	_	
20-9	4000-4001	.	_	_	
20-10	4001-4002	,	_	_	
20-11	4003-4023	hydroxybenzotriazole	_	_	
20-12	4024-4025	(	_	_	
20-13	4025-4029	HOBt	_	_	
20-14	4029-4030	)	_	_	
20-15	4030-4031	,	_	_	
20-16	4032-4035	etc	_	_	
20-17	4035-4036	.	_	_	
20-18	4036-4037	)	_	_	
20-19	4038-4042	have	_	_	
20-20	4043-4050	reduced	_	_	
20-21	4051-4055	this	_	_	
20-22	4056-4063	racemic	_	_	
20-23	4064-4070	effect	_	_	
20-24	4070-4071	,	_	_	
20-25	4072-4090	carbodiimide-based	_	_	
20-26	4091-4098	methods	_	_	
20-27	4099-4105	remain	_	_	
20-28	4106-4107	a	_	_	
20-29	4108-4112	less	_	_	
20-30	4113-4122	practical	_	_	
20-31	4123-4131	approach	_	_	
20-32	4132-4135	for	_	_	
20-33	4136-4148	synthesizing	_	_	
20-34	4149-4160	polypeptide	_	_	
20-35	4161-4170	molecules	_	_	
20-36	4170-4171	.	_	_	
20-37	4172-4173	[	_	_	
20-38	4173-4177	0040	_	_	
20-39	4177-4178	]	_	_	
20-40	4179-4182	One	_	_	
20-41	4183-4192	effective	_	_	
20-42	4193-4199	method	_	_	
20-43	4200-4203	for	_	_	
20-44	4204-4216	synthesizing	_	_	
20-45	4217-4229	polypeptides	_	_	
20-46	4230-4232	or	_	_	
20-47	4233-4247	peptide-linked	_	_	
20-48	4248-4256	polymers	_	_	
20-49	4257-4261	that	_	_	
20-50	4262-4271	overcomes	_	_	
20-51	4272-4278	issues	_	_	
20-52	4279-4281	of	_	_	
20-53	4282-4294	racemization	_	_	
20-54	4295-4298	and	_	_	
20-55	4299-4314	non-spontaneous	_	_	
20-56	4315-4329	polymerization	_	_	
20-57	4330-4332	is	_	_	
20-58	4333-4336	the	_	_	
20-59	4337-4351	Fuchs-Farthing	_	_	
20-60	4352-4360	approach	_	_	
20-61	4361-4363	of	_	_	
20-62	4364-4374	generating	_	_	
20-63	4375-4381	highly	_	_	
20-64	4382-4390	reactive	_	_	
20-65	4391-4409	N-carboxyanhydride	_	_	
20-66	4410-4411	(	_	_	
20-67	4411-4414	NCA	_	_	
20-68	4414-4415	)	_	_	
20-69	4416-4429	intermediates	_	_	
20-70	4430-4432	of	_	_	
20-71	4433-4442	compounds	_	_	
20-72	4443-4445	or	_	_	
20-73	4446-4451	amino	_	_	
20-74	4452-4457	acids	_	_	
20-75	4457-4458	.	_	_	

#Text=Unlike the carbodiimide approach discussed above, this NCA-based method preserves the stereoisomeric state of compounds or amino acids incorporated into a growing polypeptide or polymer chain, i.e., such NCA-based methods are stereospecific.
21-1	4459-4465	Unlike	_	_	
21-2	4466-4469	the	_	_	
21-3	4470-4482	carbodiimide	_	_	
21-4	4483-4491	approach	_	_	
21-5	4492-4501	discussed	_	_	
21-6	4502-4507	above	_	_	
21-7	4507-4508	,	_	_	
21-8	4509-4513	this	_	_	
21-9	4514-4523	NCA-based	*[3]	22-6[4_3]	
21-10	4524-4530	method	*[3]	_	
21-11	4531-4540	preserves	_	_	
21-12	4541-4544	the	_	_	
21-13	4545-4559	stereoisomeric	_	_	
21-14	4560-4565	state	_	_	
21-15	4566-4568	of	_	_	
21-16	4569-4578	compounds	_	_	
21-17	4579-4581	or	_	_	
21-18	4582-4587	amino	_	_	
21-19	4588-4593	acids	_	_	
21-20	4594-4606	incorporated	_	_	
21-21	4607-4611	into	_	_	
21-22	4612-4613	a	_	_	
21-23	4614-4621	growing	_	_	
21-24	4622-4633	polypeptide	_	_	
21-25	4634-4636	or	_	_	
21-26	4637-4644	polymer	_	_	
21-27	4645-4650	chain	_	_	
21-28	4650-4651	,	_	_	
21-29	4652-4655	i.e	_	_	
21-30	4655-4656	.	_	_	
21-31	4656-4657	,	_	_	
21-32	4658-4662	such	_	_	
21-33	4663-4672	NCA-based	_	_	
21-34	4673-4680	methods	_	_	
21-35	4681-4684	are	_	_	
21-36	4685-4699	stereospecific	_	_	
21-37	4699-4700	.	_	_	

#Text=Thus, products formed by this method will have normal peptide bonds which may be recognized and hydrolyzed by, for example, proteases, as well as other natural enzymes.
#Text=[0041] In general, NCA-based methods for synthesizing polymers, such as polypeptides, peptide-linked compounds, etc., may involve two basic reactions: (1) formation of one or more NCA-containing monomer(s) from one or more types of monomer(s), and (2) polymerization of these monomer(s) to form a desired polymer product(s) upon introduction of at least one type of initiator.
22-1	4701-4705	Thus	_	_	
22-2	4705-4706	,	_	_	
22-3	4707-4715	products	_	_	
22-4	4716-4722	formed	_	_	
22-5	4723-4725	by	_	_	
22-6	4726-4730	this	*[4]	_	
22-7	4731-4737	method	*[4]	_	
22-8	4738-4742	will	_	_	
22-9	4743-4747	have	_	_	
22-10	4748-4754	normal	_	_	
22-11	4755-4762	peptide	_	_	
22-12	4763-4768	bonds	_	_	
22-13	4769-4774	which	_	_	
22-14	4775-4778	may	_	_	
22-15	4779-4781	be	_	_	
22-16	4782-4792	recognized	_	_	
22-17	4793-4796	and	_	_	
22-18	4797-4807	hydrolyzed	_	_	
22-19	4808-4810	by	_	_	
22-20	4810-4811	,	_	_	
22-21	4812-4815	for	_	_	
22-22	4816-4823	example	_	_	
22-23	4823-4824	,	_	_	
22-24	4825-4834	proteases	_	_	
22-25	4834-4835	,	_	_	
22-26	4836-4838	as	_	_	
22-27	4839-4843	well	_	_	
22-28	4844-4846	as	_	_	
22-29	4847-4852	other	_	_	
22-30	4853-4860	natural	_	_	
22-31	4861-4868	enzymes	_	_	
22-32	4868-4869	.	_	_	
22-33	4870-4871	[	_	_	
22-34	4871-4875	0041	_	_	
22-35	4875-4876	]	_	_	
22-36	4877-4879	In	_	_	
22-37	4880-4887	general	_	_	
22-38	4887-4888	,	_	_	
22-39	4889-4898	NCA-based	_	_	
22-40	4899-4906	methods	_	_	
22-41	4907-4910	for	_	_	
22-42	4911-4923	synthesizing	_	_	
22-43	4924-4932	polymers	_	_	
22-44	4932-4933	,	_	_	
22-45	4934-4938	such	_	_	
22-46	4939-4941	as	_	_	
22-47	4942-4954	polypeptides	_	_	
22-48	4954-4955	,	_	_	
22-49	4956-4970	peptide-linked	_	_	
22-50	4971-4980	compounds	_	_	
22-51	4980-4981	,	_	_	
22-52	4982-4985	etc	_	_	
22-53	4985-4986	.	_	_	
22-54	4986-4987	,	_	_	
22-55	4988-4991	may	_	_	
22-56	4992-4999	involve	_	_	
22-57	5000-5003	two	_	_	
22-58	5004-5009	basic	_	_	
22-59	5010-5019	reactions	_	_	
22-60	5019-5020	:	_	_	
22-61	5021-5022	(	_	_	
22-62	5022-5023	1	_	_	
22-63	5023-5024	)	_	_	
22-64	5025-5034	formation	_	_	
22-65	5035-5037	of	_	_	
22-66	5038-5041	one	_	_	
22-67	5042-5044	or	_	_	
22-68	5045-5049	more	_	_	
22-69	5050-5064	NCA-containing	_	_	
22-70	5065-5072	monomer	_	_	
22-71	5072-5073	(	_	_	
22-72	5073-5074	s	_	_	
22-73	5074-5075	)	_	_	
22-74	5076-5080	from	_	_	
22-75	5081-5084	one	_	_	
22-76	5085-5087	or	_	_	
22-77	5088-5092	more	_	_	
22-78	5093-5098	types	_	_	
22-79	5099-5101	of	_	_	
22-80	5102-5109	monomer	_	_	
22-81	5109-5110	(	_	_	
22-82	5110-5111	s	_	_	
22-83	5111-5112	)	_	_	
22-84	5112-5113	,	_	_	
22-85	5114-5117	and	_	_	
22-86	5118-5119	(	_	_	
22-87	5119-5120	2	_	_	
22-88	5120-5121	)	_	_	
22-89	5122-5136	polymerization	_	_	
22-90	5137-5139	of	_	_	
22-91	5140-5145	these	_	_	
22-92	5146-5153	monomer	_	_	
22-93	5153-5154	(	_	_	
22-94	5154-5155	s	_	_	
22-95	5155-5156	)	_	_	
22-96	5157-5159	to	_	_	
22-97	5160-5164	form	_	_	
22-98	5165-5166	a	_	_	
22-99	5167-5174	desired	_	_	
22-100	5175-5182	polymer	_	_	
22-101	5183-5190	product	_	_	
22-102	5190-5191	(	_	_	
22-103	5191-5192	s	_	_	
22-104	5192-5193	)	_	_	
22-105	5194-5198	upon	_	_	
22-106	5199-5211	introduction	_	_	
22-107	5212-5214	of	_	_	
22-108	5215-5217	at	_	_	
22-109	5218-5223	least	_	_	
22-110	5224-5227	one	_	_	
22-111	5228-5232	type	_	_	
22-112	5233-5235	of	_	_	
22-113	5236-5245	initiator	_	_	
22-114	5245-5246	.	_	_	

#Text=In the first reaction, NCA-containing monomer(s), which may include NCA-compounds and NCA-amino acids, may be formed by reacting one or more monomer(s) with a phosgene compound in an aprotic solvent to form a temporary N-chlorocarbonyl intermediate, which then cyclizes to form an NCA moiety of the NCA-containing monomer(s) with release of two HCl molecules (See, e.g., Example 1).
23-1	5247-5249	In	_	_	
23-2	5250-5253	the	_	_	
23-3	5254-5259	first	_	_	
23-4	5260-5268	reaction	_	_	
23-5	5268-5269	,	_	_	
23-6	5270-5284	NCA-containing	_	_	
23-7	5285-5292	monomer	_	_	
23-8	5292-5293	(	_	_	
23-9	5293-5294	s	_	_	
23-10	5294-5295	)	_	_	
23-11	5295-5296	,	_	_	
23-12	5297-5302	which	_	_	
23-13	5303-5306	may	_	_	
23-14	5307-5314	include	_	_	
23-15	5315-5328	NCA-compounds	_	_	
23-16	5329-5332	and	_	_	
23-17	5333-5342	NCA-amino	_	_	
23-18	5343-5348	acids	_	_	
23-19	5348-5349	,	_	_	
23-20	5350-5353	may	_	_	
23-21	5354-5356	be	_	_	
23-22	5357-5363	formed	_	_	
23-23	5364-5366	by	_	_	
23-24	5367-5375	reacting	_	_	
23-25	5376-5379	one	_	_	
23-26	5380-5382	or	_	_	
23-27	5383-5387	more	_	_	
23-28	5388-5395	monomer	_	_	
23-29	5395-5396	(	_	_	
23-30	5396-5397	s	_	_	
23-31	5397-5398	)	_	_	
23-32	5399-5403	with	_	_	
23-33	5404-5405	a	_	_	
23-34	5406-5414	phosgene	_	_	
23-35	5415-5423	compound	_	_	
23-36	5424-5426	in	_	_	
23-37	5427-5429	an	_	_	
23-38	5430-5437	aprotic	_	_	
23-39	5438-5445	solvent	_	_	
23-40	5446-5448	to	_	_	
23-41	5449-5453	form	_	_	
23-42	5454-5455	a	_	_	
23-43	5456-5465	temporary	_	_	
23-44	5466-5482	N-chlorocarbonyl	_	_	
23-45	5483-5495	intermediate	_	_	
23-46	5495-5496	,	_	_	
23-47	5497-5502	which	_	_	
23-48	5503-5507	then	_	_	
23-49	5508-5516	cyclizes	_	_	
23-50	5517-5519	to	_	_	
23-51	5520-5524	form	_	_	
23-52	5525-5527	an	_	_	
23-53	5528-5531	NCA	_	_	
23-54	5532-5538	moiety	_	_	
23-55	5539-5541	of	_	_	
23-56	5542-5545	the	_	_	
23-57	5546-5560	NCA-containing	_	_	
23-58	5561-5568	monomer	_	_	
23-59	5568-5569	(	_	_	
23-60	5569-5570	s	_	_	
23-61	5570-5571	)	_	_	
23-62	5572-5576	with	_	_	
23-63	5577-5584	release	_	_	
23-64	5585-5587	of	_	_	
23-65	5588-5591	two	_	_	
23-66	5592-5595	HCl	_	_	
23-67	5596-5605	molecules	_	_	
23-68	5606-5607	(	_	_	
23-69	5607-5610	See	_	_	
23-70	5610-5611	,	_	_	
23-71	5612-5615	e.g	_	_	
23-72	5615-5616	.	_	_	
23-73	5616-5617	,	_	_	
23-74	5618-5625	Example	_	_	
23-75	5626-5627	1	_	_	
23-76	5627-5628	)	_	_	
23-77	5628-5629	.	_	_	
